Dr Danuta Kalinowski

Postdoctoral Research Fellow
Pathology, School of Medical Sciences

Telephone 9036 6547
Fax 9351 3429

Map

Selected grants

2015

  • A Pharmacological Targeting Approach Implementing Albumin as a Carrier of a Novel Chemotherapeutic; Kalinowski D; National Health and Medical Research Council (NHMRC)/Career Development Fellowship.

2014

  • Pharmacological Targeting of Integrated Oncogenic and Tumour Suppressive Pathways using Novel Therapeutics; Richardson D, Kovacevic Z, Kalinowski D; National Health and Medical Research Council (NHMRC)/Project Grants.
  • CLARIOstar Multifunctional Microplate Reader for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Huang M, Scolyer R, Fraser S, Sahni S, Speranza T, Owens T, Barrs V, Ju Y, Kovacevic Z, Lu Z, Camp A, Slobedman B, Morris B, Oliver B, Dos Remedios C, Kalinowski D, Fu D, Lai D, Lovicu F, Allbutt H, Triccas J, Burgess J, Kril J, Dixon K, Rendina L, Byrne M, King N, Groundwater P, Williamson P, Ho J, Dong Q, Bao B, Assinder S, McLennan S, Richardson D, Ammit A, Sharland A, Hardikar A, Hong A, Hambly B, Lee C, Murphy C, Goldsbury C, Johnstone D, Lane D, Hibbs D, Joshua D, Huq F, Halliday G, Sutherland G, Zreiqat H, Lok H, Lyons G, Jansson P, Black J, Zhu L, Sunde M, Day M, Naylor M, Buckland M, Murray M, Shafie N, Lay P, Poronnik P, Codd R, Mason R, Ryan R, Christopherson R, de Graaf S; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • A Pharmacological Targeting Approach Implementing Albumin as a Carrier of a Novel Chemotherapeutic; Kalinowski D, Lovejoy D, Suryo Rahmanto Y, Ponka P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • QX100 Droplet Digital PCR system for Shared Used at the Open Access, Multi-User Molecular Biology Core Facility; Richardson D, Kril J, Murphy C, Vandenberg R, Rendina L, Dos Remedios C, Ju Y, Kovacevic Z, Lyons G, Sutherland G, Lay P, Ammit A, Lai D, Morris B, Day M, Dong Q, Bao B, Huang M, Camp A, Boyer M, Whittington R, Byrne M, Hanrahan J, Fu D, Jansson P, Lane D, Bagley E, Hibbs D, Zhang D, Fraser S, Scolyer R, Black J, Halliday G, Christie M, Zreiqat H, Murray M, Slobedman B, Naylor M, Burgess J, Triccas J, Mason R, Chadban S, Combes V, Lovicu F, McLennan S, Kalinowski D, Sharland A, Johnstone D, Groundwater P, Dixon K, Zhou F, Lovejoy D, Lu Z, Zhu L, Goldsbury C, Witting P, Buckland M, Assinder S, Purdie (Williams) A, Codd R, Owens T, Hambly B; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Robotic High Throughput Western Analysis for the Open Access, Multi-User Sydney Cancer Research Core Facility; Richardson D, Scolyer R, Boyer M, Halliday G, Damian D, Christopherson R, Joshua D, Kench J, Hong A, Murray M, Lee C, Kalinowski D, Naylor M, Lay P, Lyons G, Kovacevic Z, Mason R, Dixon K, Chan-Ling T, Hawkins C, Sunde M, Lovejoy D, Owens T, Rendina L, Jansson P, Dos Remedios C, Charles (nee Slaviero) K, Lane D, Witting P, Dong Q, Ammit A, Groundwater P, Assinder S, Bao B, Byrne S, Zhou F, Buckland M, Grewal T, Huq F, Lai D, Codd R, Zhang D, Fu D, de Graaf S, Huang M, Payne R, Slobedman B, Barrs V, Ho J, Williamson P, Murphy C; DVC Research/Equipment Grant.

2012

  • GeneAtlas Personal Microarray System; Richardson D, Scolyer R, Stocker R, Weninger W, Black J, Allen D, Murray M, Mason R, Twigg S, King N, Horvath L, Lovicu F, Lee C, Halliday G, Lovejoy D, Joshua D, Sharland A, Roufogalis B, Hambly B, Morris B, Bao B, Bishop A, Hibbs D, Lane D, Zhou F, Hanrahan J, Dixon K, Rendina L, Byrne M, Naylor M, Cole N, Jansson P, Dong Q, Codd R, Payne R, Assinder S, Chadban S, Fraser S, McLennan S, Suryo Rahmanto A, Lai D, Yu Y, Ju Y, Buckland M, Kovacevic Z, Saletta F, Zreiqat H, Kalinowski D, Groundwater P, Simes R, Zhang D, Boyer M, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2011

  • PyroMark Q96 ID system; Richardson D, Stone J, Black J, King N, Mason R, Hunt N, Kril J, Murray M, Scolyer R, Halliday G, Vandenberg R, McMinn P, Chadban S, Byrne M, Ryan R, Dong Q, Lee C, Bishop A, Haass N, Fraser S, Hambly B, Sharland A, Kalinowski D, Assinder S, Yu Y, Bao B, Ju Y, Lovejoy D, Buckland M, Lane D, Dos Remedios C, Kovacevic Z, Sutherland G, Zhang D, Morris B, Suryo Rahmanto A, Murphy C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • The Effect of Anthracyclines on the Iron Metabolism of Leukaemia Cells.; Richardson D, Kalinowski D; Cancer Institute New South Wales/Research Innovation Grants.

2009

  • Development of Novel Drugs for the Treatment of Breast Cancer; Jansson P, Richardson D, Lovejoy D, Kalinowski D; Australian Rotary Health Research Fund/Research Support.
  • Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class; Richardson D, Kalinowski D, Lovejoy D, Bernhardt P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Molecular Examination of the Role of Iron in Oestrogen-Dependant and -independant Growth of Breast Cancer Cells; Kalinowski D, Lovejoy D, Richardson D; Cancer Institute New South Wales/Research Innovation Grants.
  • Development of Novel Anti-Cancer Drugs with Marked and Selective Activity that Overcome Resistance to established Chemotherapy; Kalinowski D, Richardson D; Cancer Institute New South Wales/Early Career Development Fellowship.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Kalinowski, D., Richardson, D. (2008). Cellular and Molecular Biology of Iron-Binding Proteins. In Rudolfs K. Zalups, D. James Koropatnick (Eds.), Cellular and Molecular Biology of Metals.

Journals

  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Lok, H., Sahni, S., Richardson, V., Kalinowski, D., Kovacevic, Z., Lane, D., Richardson, D. (2014). Glutathione S-Transferase and MRP1 Form an Integrated System Involved in the Storage and Transport of Dinitrosyl-Dithiolato Iron Complexes in Cells. Free Radical Biology and Medicine, 75(C), 14-29. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1845 (1), 1-19. [More Information]
  • Ellis, S., Kalinowski, D., Leotta, L., Huang, M., Jelfs, P., Sintchenko, V., Richardson, D., Triccas, J. (2014). Potent Anti-Mycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analogue, 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 85(2), 269-278. [More Information]
  • Potuckova, E., Jansova, H., Machacek, M., Vavrova, A., Haskova, P., Tichotova, L., Richardson, V., Kalinowski, D., Richardson, D., Simunek, T. (2014). Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS One, 9(2), 1-15. [More Information]
  • Stariat, J., Suprunova, V., Roh, J., Sestak, V., Eisner, T., Filipsky, T., Mladenka, P., Nobilis, M., Simunek, T., Klimes, J., Kalinowski, D., Richardson, D., et al (2014). Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats. Biomedical Chromatography, 28(5), 621-629. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2014). Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: Structure-activity relationship studies on their anti-proliferative and iron chelation efficacy. Journal of Inorganic Biochemistry, 141(C), 43-54. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. The Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2014). Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in Physiology, 5, 299. [More Information]
  • Stefani, C., Jansson, P., Gutierrez, E., Bernhardt, P., Richardson, D., Kalinowski, D. (2013). Alkyl Substituted 2'-Benzoylpyridine Thiosemicarbazone Chelators with Potent and Selective Anti-Neoplastic Activity: Novel Ligands that Limit Methemoglobin Formation. Journal of Medicinal Chemistry, 56(1), 357-370. [More Information]
  • Walcourt, A., Kurantsin-Mills, J., Kwagyan, J., Adenuga, B., Kalinowski, D., Lovejoy, D., Lane, D., Richardson, D. (2013). Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: Effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. Journal of Inorganic Biochemistry, 129, 43-51. [More Information]
  • Merlot, A., Pantarat, N., Menezes, S., Sahni, S., Richardson, D., Kalinowski, D. (2013). Cellular Uptake of the Antitumor Agent Dp44mT Occurs via a Carrier/Receptor-Mediated Mechanism. Molecular Pharmacology, 84(6), 911-924. [More Information]
  • Ford, S., Obeidy, P., Lovejoy, D., Bedford, M., Nichols, L., Chadwick, C., Tucker, O., Lui, G., Kalinowski, D., Jansson, P., Richardson, D., et al (2013). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. British Journal of Pharmacology, 168(6), 1316-1328. [More Information]
  • Stariat, J., Kovarikova, P., Kucera, R., Klimes, J., Kalinowski, D., Richardson, D., Ketola, R. (2013). Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry, 405(5), 1651-1661. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2013). Novel Chelators for Cancer Treatment: Where Are We Now? Antioxidants & Redox Signaling, 18(8), 973-1006. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity. Organic and Biomolecular Chemistry, 11(37), 6414-6425. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: Novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorganic & Medicinal Chemistry Letters, 23(4), 967-974. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]
  • Debebe, Z., Nekhai, S., Ashenafi, M., Lovejoy, D., Kalinowski, D., Gordeuk, V., Byrnes, W., Richardson, D., Karla, P. (2012). Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 906, 25-32. [More Information]
  • Basha, M., Chartres, J., Pantarat, N., Akbar Ali, M., Mirza, A., Kalinowski, D., Richardson, D., Bernhardt, P. (2012). Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity. Dalton Transactions: an international journal of inorganic, organometallic and bioinorganic chemistry, 41(21), 6536-6548. [More Information]
  • Brychtova, K., Dvorakova, L., Opatrilova, R., Raich, I., Kacerova, S., Placek, L., Kalinowski, D., Richardson, D., Jampilek, J. (2012). Investigation of substituted 6-aminohexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 20(1), 86-95. [More Information]
  • Stariat, J., Sestak, V., Vavrova, K., Nobilis, M., Kollarova, Z., Klimes, J., Kalinowski, D., Richardson, D., Kovarikova, P. (2012). LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and Bioanalytical Chemistry, 403(1), 309-321. [More Information]
  • Quach, P., Gutierrez, E., Basha, M., Kalinowski, D., Sharpe, P., Lovejoy, D., Bernhardt, P., Jansson, P., Richardson, D. (2012). Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect. Molecular Pharmacology, 82(1), 105-114. [More Information]
  • Lok, H., Suryo Rahmanto, Y., Hawkins, C., Kalinowski, D., Morrow, C., Townsend, A., Ponka, P., Richardson, D. (2012). Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and Multidrug Resistant Protein 1 via Dinitrosyl iron complexes. Journal of Biological Chemistry, 287(1), 607-618. [More Information]
  • Suryo Rahmanto, Y., Kalinowski, D., Lane, D., Lok, H., Richardson, V., Richardson, D. (2012). Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-Lived NO that is Trafficked by Interacting Proteins. Journal of Biological Chemistry, 287(10), 6960-6968. [More Information]
  • Lovejoy, D., Sharp, D., Seebacher, N., Obeidy, P., Prichard, T., Stefani, C., Basha, M., Sharpe, P., Jansson, P., Kalinowski, D., Richardson, D., et al (2012). Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo. Journal of Medicinal Chemistry, 55(16), 7230-7244. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]
  • Stefani, C., Punnia-Moorthy, G., Lovejoy, D., Jansson, P., Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2011). Halogenated 2'-Benzoylpyridine Thiosemicarbazone (XBpT) Chelators with Potent and Selective Anti-Neoplastic Activity: Relationship to Intracellular Redox Activity. Journal of Medicinal Chemistry, 54(19), 6936-6948. [More Information]
  • Debebe, Z., Ammosova, T., Breuer, D., Lovejoy, D., Kalinowski, D., Karla, P., Kumar, K., Jarebtsova, M., Ray, P., Kashanchi, F., Richardson, D., et al (2011). Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Molecular Pharmacology, 79(1), 185-196. [More Information]
  • Sharpe, P., Richardson, D., Kalinowski, D., Bernhardt, P. (2011). Synthetic and natural products as iron chelators. Current Topics in Medicinal Chemistry, 11(5), 591-607. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]
  • Miao, Q., Xu, D., Wang, Z., Xu, L., Wang, T., Wu, Y., Lovejoy, D., Kalinowski, D., Richardson, D., Nie, G., et al (2010). Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials, 31(28), 7364-7375. [More Information]
  • Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D., Kovarikova, P., Vavrova, K., Richardson, D., et al (2010). Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 23(6), 1105-1114. [More Information]
  • Liu, J., Obando Gutierrez, D., Schipanski, L., Groebler, L., Witting, P., Kalinowski, D., Richardson, D., Codd, R. (2010). Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry, 53(3), 1370-1382. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Kalinowski, D., Richardson, D. (2010). Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Analytical and Bioanalytical Chemistry, 397(1), 161-171. [More Information]
  • Brychtova, K., Opatrilova, R., Raich, I., Kalinowski, D., Dvorakova, L., Placek, L., Csollei, J., Richardson, D., Jampilek, J. (2010). Investigating the activity of 2-substituted alkyl-6-(25-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 18(24), 8556-8565. [More Information]
  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]
  • Merlot, A., Pantarat, N., Lovejoy, D., Kalinowski, D., Richardson, D. (2010). Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular Pharmacology, 78(4), 675-684. [More Information]
  • Richardson, D., Kalinowski, D., Richardson, V., Sharpe, P., Lovejoy, D., Islam, M., Bernhardt, P. (2009). 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. Journal of Medicinal Chemistry, 52(5), 1459-1470. [More Information]
  • Noulsri, E., Richardson, D., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D., Pattanapanyasat, K. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal Of Hematology, 84(3), 170-176. [More Information]
  • Richardson, D., Kalinowski, D., Lau, S., Jansson, P., Lovejoy, D. (2009). Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. BBA - Bioenergetics, 1790 (7), 702-717. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877(3), 316-322. [More Information]
  • Bernhardt, P., Sharpe, P., Islam, M., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of Medicinal Chemistry, 52(2), 407-415. [More Information]
  • Mladenka, P., Kalinowski, D., Haskova, P., Bobrovova, Z., Hrdina, R., Simunek, T., Nachtigal, P., Semecky, V., Vavrova, J., Holeckova, M., Jansson, P., Richardson, D., et al (2009). The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 22(1), 208-217. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]
  • Kalinowski, D., Quach, P., Richardson, D. (2009). Thiosemicarbazones: the new wave in cancer treatment. Future Medicinal Chemistry, 1(6), 1143-1151. [More Information]
  • Opletalova, V., Kalinowski, D., Vesjova, M., Kunes, J., Pour, M., Jampılek, J., Buchta, V., Richardson, D. (2008). Identification and Characterization of Thiosemicarbazones with Antifungal and Antitumor Effects: Cellular Iron Chelation Mediating Cytotoxic Activity. Chemical Research in Toxicology, 21(9), 1878-1889. [More Information]
  • Lim, C., Kalinowski, D., Richardson, D. (2008). Protection Against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class. Molecular Pharmacology, 74(1), 225-235. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2008). Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Journal of Medicinal Chemistry, 51(2), 331-344. [More Information]
  • Bernhardt, P., Wilson, G., Sharpe, P., Kalinowski, D., Richardson, D. (2008). Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. Journal of Biological Inorganic Chemistry, 13(1), 107-119. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. Journal of Medicinal Chemistry, 50(24), 6212-6225. [More Information]
  • Kalinowski, D., Yu, Y., Sharpe, P., Islam, M., Liao, Y., Lovejoy, D., Kumar, N., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of Medicinal Chemistry, 50(15), 3716-3729. [More Information]
  • Mrkvicková, Z., Kovaríková, P., Klimes, J., Kalinowski, D., Richardson, D. (2007). Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of Pharmaceutical and Biomedical Analysis, 43(4), 1343-1351. [More Information]
  • Kalinowski, D., Richardson, D. (2007). Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chemical Research in Toxicology, 20(5), 715-720. [More Information]
  • Musiol, R., Jampilek, J., Kralova, K., Richardson, D., Kalinowski, D., Podeszwa, B., Finster, J., Niedbala, H., Palka, A., Polanski, J. (2007). Investigating biological activity spectrum for novel quinoline analogues. Bioorganic and Medicinal Chemistry, 15(3), 1280-1288. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(22), 6138-6141. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative and styrylquinolinecarboxyli activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(22), 6138-6141. [More Information]
  • Mizdrak, J., Hains, P., Kalinowski, D., Truscott, R., Davies, M., Jamie, J. (2007). Novel human lens metabolites from normal and cataractous human lenses. Tetrahedron, 63(23), 4990-4999.
  • Yu, Y., Wong, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2006). Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clinical Cancer Research, 12(23), 6876-6883. [More Information]
  • Richardson, D., Sharpe, P., Lovejoy, D., Senaratne, D., Kalinowski, D., Islam, M., Bernhardt, P. (2006). Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. Journal of Medicinal Chemistry, 49(22), 6510-6521. [More Information]
  • Lovejoy, D., Kalinowski, D., Bernhardt, P., Richardson, D. (2006). PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease. Hemoglobin, 30(1), 93-104. [More Information]
  • Kalinowski, D., Richardson, D. (2005). The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews, 57(4), 547-583. [More Information]

2014

  • Lane, D., Mills, T., Shafie, N., Merlot, A., Saleh Moussa, R., Kalinowski, D., Kovacevic, Z., Richardson, D. (2014). Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition. Biochimica et Biophysica Acta-Reviews on Cancer, 1845 (2), 166-181. [More Information]
  • Lok, H., Sahni, S., Richardson, V., Kalinowski, D., Kovacevic, Z., Lane, D., Richardson, D. (2014). Glutathione S-Transferase and MRP1 Form an Integrated System Involved in the Storage and Transport of Dinitrosyl-Dithiolato Iron Complexes in Cells. Free Radical Biology and Medicine, 75(C), 14-29. [More Information]
  • Fang, B., Kovacevic, Z., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S., Richardson, D. (2014). Molecular Functions of the Iron-Regulated Metastasis Suppressor, NDRG1, and its Potential as a Molecular Target for Cancer Therapy. Biochimica et Biophysica Acta (Molecular and Cell Biology of Lipids), 1845 (1), 1-19. [More Information]
  • Ellis, S., Kalinowski, D., Leotta, L., Huang, M., Jelfs, P., Sintchenko, V., Richardson, D., Triccas, J. (2014). Potent Anti-Mycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analogue, 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 85(2), 269-278. [More Information]
  • Potuckova, E., Jansova, H., Machacek, M., Vavrova, A., Haskova, P., Tichotova, L., Richardson, V., Kalinowski, D., Richardson, D., Simunek, T. (2014). Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS One, 9(2), 1-15. [More Information]
  • Stariat, J., Suprunova, V., Roh, J., Sestak, V., Eisner, T., Filipsky, T., Mladenka, P., Nobilis, M., Simunek, T., Klimes, J., Kalinowski, D., Richardson, D., et al (2014). Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats. Biomedical Chromatography, 28(5), 621-629. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2014). Synthesis and biological evaluation of 2-benzoylpyridine thiosemicarbazones in a dimeric system: Structure-activity relationship studies on their anti-proliferative and iron chelation efficacy. Journal of Inorganic Biochemistry, 141(C), 43-54. [More Information]
  • Sahni, S., Bae, D., Lane, D., Kovacevic, Z., Kalinowski, D., Jansson, P., Richardson, D. (2014). The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. The Journal of Biological Chemistry, 289(14), 9692-9709. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2014). Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in Physiology, 5, 299. [More Information]

2013

  • Stefani, C., Jansson, P., Gutierrez, E., Bernhardt, P., Richardson, D., Kalinowski, D. (2013). Alkyl Substituted 2'-Benzoylpyridine Thiosemicarbazone Chelators with Potent and Selective Anti-Neoplastic Activity: Novel Ligands that Limit Methemoglobin Formation. Journal of Medicinal Chemistry, 56(1), 357-370. [More Information]
  • Walcourt, A., Kurantsin-Mills, J., Kwagyan, J., Adenuga, B., Kalinowski, D., Lovejoy, D., Lane, D., Richardson, D. (2013). Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: Effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. Journal of Inorganic Biochemistry, 129, 43-51. [More Information]
  • Merlot, A., Pantarat, N., Menezes, S., Sahni, S., Richardson, D., Kalinowski, D. (2013). Cellular Uptake of the Antitumor Agent Dp44mT Occurs via a Carrier/Receptor-Mediated Mechanism. Molecular Pharmacology, 84(6), 911-924. [More Information]
  • Ford, S., Obeidy, P., Lovejoy, D., Bedford, M., Nichols, L., Chadwick, C., Tucker, O., Lui, G., Kalinowski, D., Jansson, P., Richardson, D., et al (2013). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. British Journal of Pharmacology, 168(6), 1316-1328. [More Information]
  • Stariat, J., Kovarikova, P., Kucera, R., Klimes, J., Kalinowski, D., Richardson, D., Ketola, R. (2013). Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry, 405(5), 1651-1661. [More Information]
  • Merlot, A., Kalinowski, D., Richardson, D. (2013). Novel Chelators for Cancer Treatment: Where Are We Now? Antioxidants & Redox Signaling, 18(8), 973-1006. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Structure-activity studies of 4-phenyl-substituted 2'-benzoylpyridine thiosemicarbazones with potent and selective anti-tumour activity. Organic and Biomolecular Chemistry, 11(37), 6414-6425. [More Information]
  • Lukmantara, A., Kalinowski, D., Kumar, N., Richardson, D. (2013). Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: Novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorganic & Medicinal Chemistry Letters, 23(4), 967-974. [More Information]
  • Lui, G., Obeidy, P., Ford, S., Tselepis, C., Sharp, D., Jansson, P., Kalinowski, D., Kovacevic, Z., Lovejoy, D., Richardson, D. (2013). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 83(1), 179-190. [More Information]
  • Kalinowski, D., Jansson, P., Kovacevic, Z., Richardson, D. (2013). The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 18(2), 48-50. [More Information]
  • Bae, D., Jansson, P., Huang, M., Kovacevic, Z., Kalinowski, D., Lee, C., Sahni, S., Richardson, D. (2013). The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 66(11), 911-917. [More Information]

2012

  • Debebe, Z., Nekhai, S., Ashenafi, M., Lovejoy, D., Kalinowski, D., Gordeuk, V., Byrnes, W., Richardson, D., Karla, P. (2012). Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 906, 25-32. [More Information]
  • Basha, M., Chartres, J., Pantarat, N., Akbar Ali, M., Mirza, A., Kalinowski, D., Richardson, D., Bernhardt, P. (2012). Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity. Dalton Transactions: an international journal of inorganic, organometallic and bioinorganic chemistry, 41(21), 6536-6548. [More Information]
  • Brychtova, K., Dvorakova, L., Opatrilova, R., Raich, I., Kacerova, S., Placek, L., Kalinowski, D., Richardson, D., Jampilek, J. (2012). Investigation of substituted 6-aminohexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 20(1), 86-95. [More Information]
  • Stariat, J., Sestak, V., Vavrova, K., Nobilis, M., Kollarova, Z., Klimes, J., Kalinowski, D., Richardson, D., Kovarikova, P. (2012). LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and Bioanalytical Chemistry, 403(1), 309-321. [More Information]
  • Quach, P., Gutierrez, E., Basha, M., Kalinowski, D., Sharpe, P., Lovejoy, D., Bernhardt, P., Jansson, P., Richardson, D. (2012). Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect. Molecular Pharmacology, 82(1), 105-114. [More Information]
  • Lok, H., Suryo Rahmanto, Y., Hawkins, C., Kalinowski, D., Morrow, C., Townsend, A., Ponka, P., Richardson, D. (2012). Nitric oxide storage and transport in cells are mediated by glutathione S-transferase P1-1 and Multidrug Resistant Protein 1 via Dinitrosyl iron complexes. Journal of Biological Chemistry, 287(1), 607-618. [More Information]
  • Suryo Rahmanto, Y., Kalinowski, D., Lane, D., Lok, H., Richardson, V., Richardson, D. (2012). Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-Lived NO that is Trafficked by Interacting Proteins. Journal of Biological Chemistry, 287(10), 6960-6968. [More Information]
  • Lovejoy, D., Sharp, D., Seebacher, N., Obeidy, P., Prichard, T., Stefani, C., Basha, M., Sharpe, P., Jansson, P., Kalinowski, D., Richardson, D., et al (2012). Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo. Journal of Medicinal Chemistry, 55(16), 7230-7244. [More Information]
  • Serda, M., Kalinowski, D., Mrozek-Wilczkiewicz, A., Musiol, R., Szurko, A., Ratuszna, A., Pantarat, N., Kovacevic, Z., Merlot, A., Richardson, D., et al (2012). Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 22(17), 5527-5531. [More Information]

2011

  • Stefani, C., Punnia-Moorthy, G., Lovejoy, D., Jansson, P., Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2011). Halogenated 2'-Benzoylpyridine Thiosemicarbazone (XBpT) Chelators with Potent and Selective Anti-Neoplastic Activity: Relationship to Intracellular Redox Activity. Journal of Medicinal Chemistry, 54(19), 6936-6948. [More Information]
  • Debebe, Z., Ammosova, T., Breuer, D., Lovejoy, D., Kalinowski, D., Karla, P., Kumar, K., Jarebtsova, M., Ray, P., Kashanchi, F., Richardson, D., et al (2011). Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Molecular Pharmacology, 79(1), 185-196. [More Information]
  • Sharpe, P., Richardson, D., Kalinowski, D., Bernhardt, P. (2011). Synthetic and natural products as iron chelators. Current Topics in Medicinal Chemistry, 11(5), 591-607. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Yu, Y., Suryo Rahmanto, Y., Sharpe, P., Bernhardt, P., Richardson, D. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 11(5), 483-499. [More Information]

2010

  • Miao, Q., Xu, D., Wang, Z., Xu, L., Wang, T., Wu, Y., Lovejoy, D., Kalinowski, D., Richardson, D., Nie, G., et al (2010). Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials, 31(28), 7364-7375. [More Information]
  • Bendova, P., Mackova, E., Haskova, P., Vavrova, A., Jirkovsky, E., Sterba, M., Popelova, O., Kalinowski, D., Kovarikova, P., Vavrova, K., Richardson, D., et al (2010). Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 23(6), 1105-1114. [More Information]
  • Liu, J., Obando Gutierrez, D., Schipanski, L., Groebler, L., Witting, P., Kalinowski, D., Richardson, D., Codd, R. (2010). Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry, 53(3), 1370-1382. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Kalinowski, D., Richardson, D. (2010). Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Analytical and Bioanalytical Chemistry, 397(1), 161-171. [More Information]
  • Brychtova, K., Opatrilova, R., Raich, I., Kalinowski, D., Dvorakova, L., Placek, L., Csollei, J., Richardson, D., Jampilek, J. (2010). Investigating the activity of 2-substituted alkyl-6-(25-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers. Bioorganic and Medicinal Chemistry, 18(24), 8556-8565. [More Information]
  • Mrozek-Wilczkiewicz, A., Kalinowski, D., Musiol, R., Finster, J., Szurko, A., Serafin, K., Knas, M., Kamalapuram, S., Kovacevic, Z., Jampilek, J., Richardson, D., et al (2010). Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 18(7), 2664-2671. [More Information]
  • Otevrel, J., Mandelova, Z., Pesko, M., Guo, J., Kralova, K., Sersen, F., Vejsova, M., Kalinowski, D., Kovacevic, Z., Coffey, A., Richardson, D., et al (2010). Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 15(11), 8122-8142. [More Information]
  • Kovacevic, Z., Kalinowski, D., Lovejoy, D., Quach, P., Burn (Wong), J., Richardson, D. (2010). Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 7(3), 194-207. [More Information]
  • Merlot, A., Pantarat, N., Lovejoy, D., Kalinowski, D., Richardson, D. (2010). Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular Pharmacology, 78(4), 675-684. [More Information]

2009

  • Richardson, D., Kalinowski, D., Richardson, V., Sharpe, P., Lovejoy, D., Islam, M., Bernhardt, P. (2009). 2-Acetylpyridine Thiosemicarbazones are Potent Iron Chelators and Antiproliferative Agents: Redox Activity, Iron Complexation and Characterization of their Antitumor Activity. Journal of Medicinal Chemistry, 52(5), 1459-1470. [More Information]
  • Noulsri, E., Richardson, D., Lerdwana, S., Fucharoen, S., Yamagishi, T., Kalinowski, D., Pattanapanyasat, K. (2009). Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. American Journal Of Hematology, 84(3), 170-176. [More Information]
  • Richardson, D., Kalinowski, D., Lau, S., Jansson, P., Lovejoy, D. (2009). Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. BBA - Bioenergetics, 1790 (7), 702-717. [More Information]
  • Stariat, J., Kovarikova, P., Klimes, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877(3), 316-322. [More Information]
  • Bernhardt, P., Sharpe, P., Islam, M., Lovejoy, D., Kalinowski, D., Richardson, D. (2009). Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of Medicinal Chemistry, 52(2), 407-415. [More Information]
  • Mladenka, P., Kalinowski, D., Haskova, P., Bobrovova, Z., Hrdina, R., Simunek, T., Nachtigal, P., Semecky, V., Vavrova, J., Holeckova, M., Jansson, P., Richardson, D., et al (2009). The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 22(1), 208-217. [More Information]
  • Yu, Y., Kalinowski, D., Kovacevic, Z., Siafakas, A., Jansson, P., Stefani, C., Lovejoy, D., Sharpe, P., Bernhardt, P., Richardson, D. (2009). Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 52(17), 5271-5294. [More Information]
  • Kalinowski, D., Quach, P., Richardson, D. (2009). Thiosemicarbazones: the new wave in cancer treatment. Future Medicinal Chemistry, 1(6), 1143-1151. [More Information]

2008

  • Kalinowski, D., Richardson, D. (2008). Cellular and Molecular Biology of Iron-Binding Proteins. In Rudolfs K. Zalups, D. James Koropatnick (Eds.), Cellular and Molecular Biology of Metals.
  • Opletalova, V., Kalinowski, D., Vesjova, M., Kunes, J., Pour, M., Jampılek, J., Buchta, V., Richardson, D. (2008). Identification and Characterization of Thiosemicarbazones with Antifungal and Antitumor Effects: Cellular Iron Chelation Mediating Cytotoxic Activity. Chemical Research in Toxicology, 21(9), 1878-1889. [More Information]
  • Lim, C., Kalinowski, D., Richardson, D. (2008). Protection Against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich's Ataxia Fibroblasts using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class. Molecular Pharmacology, 74(1), 225-235. [More Information]
  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2008). Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Journal of Medicinal Chemistry, 51(2), 331-344. [More Information]
  • Bernhardt, P., Wilson, G., Sharpe, P., Kalinowski, D., Richardson, D. (2008). Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. Journal of Biological Inorganic Chemistry, 13(1), 107-119. [More Information]

2007

  • Kalinowski, D., Sharpe, P., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of New Iron Chelators with Anti-Proliferative Activity: Structure-Activity Relationships of Novel Thiohydrazone Analogues. Journal of Medicinal Chemistry, 50(24), 6212-6225. [More Information]
  • Kalinowski, D., Yu, Y., Sharpe, P., Islam, M., Liao, Y., Lovejoy, D., Kumar, N., Bernhardt, P., Richardson, D. (2007). Design, Synthesis, and Characterization of Novel Iron Chelators: Structure-Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of Medicinal Chemistry, 50(15), 3716-3729. [More Information]
  • Mrkvicková, Z., Kovaríková, P., Klimes, J., Kalinowski, D., Richardson, D. (2007). Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of Pharmaceutical and Biomedical Analysis, 43(4), 1343-1351. [More Information]
  • Kalinowski, D., Richardson, D. (2007). Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chemical Research in Toxicology, 20(5), 715-720. [More Information]
  • Musiol, R., Jampilek, J., Kralova, K., Richardson, D., Kalinowski, D., Podeszwa, B., Finster, J., Niedbala, H., Palka, A., Polanski, J. (2007). Investigating biological activity spectrum for novel quinoline analogues. Bioorganic and Medicinal Chemistry, 15(3), 1280-1288. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(22), 6138-6141. [More Information]
  • Podeszwa, B., Niedbala, H., Polanski, J., Musiol, R., Tabak, D., Finster, J., Serafin, K., Milczarek, M., Wietrzyk, J., Boryczka, S., Kalinowski, D., Richardson, D., et al (2007). Investigating the antiproliferative and styrylquinolinecarboxyli activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines. Bioorganic and Medicinal Chemistry Letters: the tetrahedron journal for research at the interface of chemistry and biology, 17(22), 6138-6141. [More Information]
  • Mizdrak, J., Hains, P., Kalinowski, D., Truscott, R., Davies, M., Jamie, J. (2007). Novel human lens metabolites from normal and cataractous human lenses. Tetrahedron, 63(23), 4990-4999.

2006

  • Yu, Y., Wong, J., Lovejoy, D., Kalinowski, D., Richardson, D. (2006). Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clinical Cancer Research, 12(23), 6876-6883. [More Information]
  • Richardson, D., Sharpe, P., Lovejoy, D., Senaratne, D., Kalinowski, D., Islam, M., Bernhardt, P. (2006). Dipyridyl Thiosemicarbazone Chelators with Potent and Selective Antitumor Activity Form Iron Complexes with Redox Activity. Journal of Medicinal Chemistry, 49(22), 6510-6521. [More Information]
  • Lovejoy, D., Kalinowski, D., Bernhardt, P., Richardson, D. (2006). PCTH: A Novel Orally Active Chelator for the Treatment of Iron Overload Disease. Hemoglobin, 30(1), 93-104. [More Information]

2005

  • Kalinowski, D., Richardson, D. (2005). The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer. Pharmacological Reviews, 57(4), 547-583. [More Information]

To update your profile click here. For support on your academic profile contact .